Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis

Author： Kotani I.   Sato A.   Hayakawa H.   Urano T.   Takada Y.   Takada A.  

Publisher： Elsevier

ISSN： 0049-3848

Source： Thrombosis Research, Vol.77, Iss.6, 1995-03, pp. : 493-504

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relevance of Tissue Factor and Tissue Factor Pathway Inhibitor for Hypercoagulable State in the Lungs of Patients with Idiopathic Pulmonary Fibrosis

By Fujii M.   Hayakawa H.   Urano T.   Sato A.   Chida K.   Nakamura H.   Takada A.  

Thrombosis Research, Vol. 99, Iss. 2, 2000-07 ,pp. : 111-117

Elsevier

Access to resources Recommend Favorite

Idiopathic Pulmonary Fibrosis: Current and Future Treatment Options

By Davies H.R.  

American Journal of Respiratory Medicine, Vol. 1, Iss. 3, 2002-03 ,pp. : 211-224

Adis International

Access to resources Recommend Favorite

Idiopathic Pulmonary Fibrosis: An EU Patient Perspective Survey

By  

Current Respiratory Medicine Reviews, Vol. 9, Iss. 2, 2013-04 ,pp. : 112-119

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis

By  

Current Respiratory Medicine Reviews, Vol. 12, Iss. 3, 2016-12 ,pp. : 186-207

Bentham Science Publishers

Access to resources Recommend Favorite

Prevalence of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis: Correlation with Physiological Parameters

By Papakosta D.  

Lung, Vol. 189, Iss. 5, 2011-10 ,pp. : 391-399

Springer Publishing Company

Access to resources Recommend Favorite